Spero Therapeutics, Inc.
SPRO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001701108
No open-market purchases or sales by Spero Therapeutics, Inc. insiders were filed in the last 90 days; 59 institutions reported holding it in 13F filings for Q2 2026, worth $47.5M in total; no superinvestor holds it.
Q2 2024 vs. Q1 2024
How the institutions holding Spero Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 54 | 48 | −6 |
| Shares | 13.8M | 13.9M | +120.0K (+0.9%) |
| Value | $23.7M | $18.0M | −$5.63M (−23.8%) |
New holders (5)
Institutions that held Spero Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citadel Advisors LLC | 312,034 | $405.6K | 0.00% |
| Two Sigma Securities, LLC | 67,728 | $88.0K | 0.00% |
| Susquehanna International Group, LLP | 23,073 | $30.0K | 0.00% |
| Royal Bank of Canada | 1,959 | $3.00K | 0.00% |
| Cullen/Frost Bankers, Inc. | 2,000 | $2.60K | 0.00% |
Sold out (11)
Institutions that held Spero Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Bank of Montreal | 79,500 | $139.9K |
| Squarepoint Ops LLC | 79,401 | $136.6K |
| Bailard, Inc. | 60,900 | $104.7K |
| Gsa Capital Partners LLP | 28,319 | $49.0K |
| Prudential Financial Inc | 25,400 | $43.7K |
| Virtu Financial LLC | 18,180 | $31.0K |
| XTX Topco Ltd | 15,013 | $25.8K |
| Lazard Asset Management LLC | 1,248 | $2.00K |
| IFP Advisors, Inc | 650 | $1.12K |
| Raleigh Capital Management Inc. | 500 | $860 |
| PFS Partners, LLC | 50 | $86 |